Skip to main content
Premium Trial:

Request an Annual Quote

Asuragen, Biogen Idec Sign Rx/Dx Co-development Pact

NEW YORK (GenomeWeb News) – Asuragen said today that it will work with Biogen Idec to develop a companion diagnostic test for a cancer drug.

Asuragen will use its RNA technologies to develop an assay that could help select which patients will benefit from a drug candidate that Biogen Idec now has in clinical development.

The Austin, Texas-based Asuragen currently offers its Signature Genetic Testing and Oncology Testing product lines, as well as its Armored RNA technology.

The Scan

Just Breathing

A new analysis suggests that most Mycobacterium tuberculosis is spread by aerosols from breathing, rather than by coughing, the New York Times reports.

Just Like This One

NPR reports that the World Health Organization has hired a South African biotech company to recreate mRNA vaccine for SARS-CoV-2 that is similar to the one developed by Moderna.

Slow Start

The Wall Street Journal reports that Biogen's Alzheimer's disease treatment had revenues for July through September that totaled $300,000.

Genome Research Papers on Cancer Chromatin, Splicing in the Thymus, Circular RNAs in Cancer

In Genome Research this week: analysis of bivalent chromatin sites, RBFOX splicing factors' role in thymic epithelial cells, and more.